Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

During pregnancy, the body must tightly control calcium levels to support both the developing fetus and the mother’s bones. A gene called CYP24A1 plays an important role in this process by breaking down calcitriol, the active form of vitamin D. When this gene does not work properly, calcitriol levels become too high, leading to dangerously elevated calcium levels in the mother. This condition, known as gestational hypercalcemia, can cause serious health problems, and current treatment options are often ineffective or unsafe during pregnancy. This research project will test new ways to safely lower calcium levels during pregnancy by targeting the pathways that control calcitriol. Using a mouse model in which CYP24A1 is not functioning, we will evaluate five potential treatments that either reduce calcitriol production or increase its breakdown. These treatments have shown promise in previous studies but have not been tested in relation to CYP24A1-deficiency during pregnancy. Pregnant mice will receive one of these treatments for four days late in gestation. We will measure how each treatment affects the mother’s calcium levels, bone strength, vitamin D hormones, and intestinal absorption of minerals. We will also examine the fetuses to assess their calcium balance, bone development, and overall health. The goal of this project is to identify which treatment is most effective at safely correcting high calcium levels during pregnancy. Understanding how to manage this condition could improve outcomes for individuals affected by CYP24A1-related disorders and other forms of pregnancy-associated hypercalcemia. Ultimately, this work may guide the development of better treatment strategies for pregnant patients experiencing life-threatening disruptions in calcium regulation.